Adverse Drug Reaction Relief System in Japan: From Clinical Perspective

Abstract

Adverse drug reaction (ADR) relief system in Japan is comprehensively described in this article. Particularly, review process during ADR relief evaluation is focused from clinical perspective. The significance of clinical review process and roles of a physician medical reviewer in the ADR relief system in Japan are also discussed. The current ADR Relief Service in Japan requires criteria for compensation eligibility including the “proper” use of the medication associated with the adverse event, and reasonably plausible association between the drug and the adverse event. The criteria are primarily reviewed at the ADR relief department of Pharmaceuticals and Medical Devices Agency (PMDA). In this article, after introducing framework of the ADR relief system in Japan including review processes at PMDA, actual process of the ADR relief assessment is described. In more details, we explain appropriate indication and appropriate usage in the ADR relief evaluation and unexpected/unwritten ADR in the Japanese package insert. Also described are time period for the payment, causality assessment between ADRs and the death, and pitfalls during the evaluation of the ADR relief system in Japan. In the last part, current issues and future directions are referred.

This is a preview of subscription content, log in to check access.

Figure 1.
Figure 2.
Figure 3.
Figure 4.

References

  1. 1.

    Outline of Relief Services for Adverse Health Effects. https://www.pmda.go.jp/english/relief-services/0002.html.

  2. 2.

    The Relief System for Sufferers from Adverse Drug Reactions, etc. Changes in the Status of Adverse Drug Reaction Relief (as of the end of each FY) (PDF:395 KB). https://www.mhlw.go.jp/english/wp/wp-hw2/part2/p3_0037.pdf.

  3. 3.

    Overview of Medical Service Regime in Japan. https://www.mhlw.go.jp/bunya/iryouhoken/iryouhoken01/dl/01_eng.pdf.

  4. 4.

    Tominaga T, Miyazaki S, Oniyama Y, Weber AD, Kondo T. The Japanese postmarketing adverse event relief system: a confluence of regulatory science, the legal system, and clinical pharmacology. Clin Therap. 2017;102(2):277–82.

    CAS  Article  Google Scholar 

  5. 5.

    PMDA annual report 2017. https://www.pmda.go.jp/english/about-pmda/annual-reports/0001.html.

  6. 6.

    The use of the WHO-UMC system for standardised case causality assessment. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf.

Download references

Acknowledgments

The authors would like to thank all the staff members in the ADR Relief Department.

Funding

No funding sources.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Meguru Watanabe MD, PhD.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Watanabe, M., Nishikawa, H., Miyasaka, N. et al. Adverse Drug Reaction Relief System in Japan: From Clinical Perspective. Ther Innov Regul Sci 54, 731–737 (2020). https://doi.org/10.1007/s43441-019-00003-7

Download citation

Keywords

  • ADR relief system
  • ADR causality assessment
  • Physician medical reviewer
  • Pharmaceuticals and Medical Devices Agency
  • ADR relief department